A Reversible Shift of Driver Dependence from EGFR to Notch1 in Non-Small Cell Lung Cancer as a Cause of Resistance to Tyrosine Kinase Inhibitors

Simple Summary Notch1 and EGFR are two surface receptors activating different cellular processes in cancer cells. EGFR, harboring activating mutations, drives unlimited cell proliferation in non-small cell lung cancer (NSCLC), and treatment of tumors with tyrosine kinase inhibitors (TKIs) results in growth arrest and cell death. On the other hand, Notch1 plays a key role in the loss of epithelial characteristics and the concomitant acquisition of mesenchymal traits and invasive potential of tumor cells. Interestingly, high levels of Notch1 are associated with the resistance to EGFR TKIs. Here, we evaluated the mechanisms by which Notch1 causes resistance of NSCLC to EGFR TKIs, and provided evidence that high levels of activated Notch1 induce a decrease of EGFR, by modulating the activity of the promoter of the EGFR gene. Therefore, blocking the Notch1 pathway in tumors treated with EGFR inhibitors would prevent EGFR downregulation, maintaining drug sensitivity. Abstract Notch1 plays a key role in epithelial-mesenchymal transition (EMT) and in the maintenance of cancer stem cells. In the present study we tested whether high levels of activated Notch1 in oncogene-driven NSCLC can induce a reversible shift of driver dependence from EGFR to Notch1, and thus causing resistance to EGFR inhibitors. Adherent cells (parental) and tumor spheres (TS) from NSCLC H1975 cells and patient-derived CD133-positive cells were tested for EGFR and Notch1 signaling cascade. The Notch1-dependent modulation of EGFR, NCID, Hes1, p53, and Sp1 were then analyzed in parental cells by binding assays with a Notch1 agonist, DLL4. TS were more resistant than parental cells to EGFR inhibitors. A strong upregulation of Notch1 and a concomitant downregulation of EGFR were observed in TS compared to parental cells. Parental cell exposure to DLL4 showed a dose-dependent decrease of EGFR and a simultaneous increase of NCID, Hes1, p53, and Sp1, along with the dislocation of Sp1 from the EGFR promoter. Furthermore, an enhanced interaction between p53 and Sp1 was observed in TS. In NSCLC cells, high levels of active Notch1 can promote a reversible shift of driver dependence from EGFR to Notch1, leading to resistance to EGFR inhibitors.

[1]  C. Paweletz,et al.  Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC , 2020, Clinical Cancer Research.

[2]  Piyush B. Gupta,et al.  Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance. , 2019, Cell stem cell.

[3]  T. Brabletz,et al.  Non-redundant functions of EMT transcription factors , 2019, Nature Cell Biology.

[4]  R. Weinberg,et al.  New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer , 2018, Nature reviews. Molecular cell biology.

[5]  Kyoung-Mee Kim,et al.  Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy , 2018, Nature Genetics.

[6]  T. Reya,et al.  Stem cell fate in cancer growth, progression and therapy resistance , 2018, Nature Reviews Cancer.

[7]  L. Dubois,et al.  Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting? , 2018, Front. Oncol..

[8]  M. Panico,et al.  Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non–Small Cell Lung Cancer Detected by 18F-fluorothymidine , 2018, Clinical Cancer Research.

[9]  S. Grossman,et al.  Gain‐of‐function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells , 2017, Molecular oncology.

[10]  R. Weinberg,et al.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications , 2017, Nature Reviews Clinical Oncology.

[11]  R. López-López,et al.  Molecular Profiling of Circulating Tumour Cells Identifies Notch1 as a Principal Regulator in Advanced Non-Small Cell Lung Cancer , 2016, Scientific Reports.

[12]  S. Grossman,et al.  Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter , 2016, Oncotarget.

[13]  Jaime Rodriguez-Canales,et al.  A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition , 2015, Clinical Cancer Research.

[14]  T. Douki,et al.  Combination of Aβ Secretion and Oxidative Stress in an Alzheimer-Like Cell Line Leads to the Over-Expression of the Nucleotide Excision Repair Proteins DDB2 and XPC , 2015, International journal of molecular sciences.

[15]  M. Stoppelli,et al.  Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[16]  Hua Wu,et al.  Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis , 2015, Scientific Reports.

[17]  Charles Swanton,et al.  Translational Implications of Tumor Heterogeneity , 2015, Clinical Cancer Research.

[18]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[19]  D. Carbone,et al.  EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling. , 2014, Cancer research.

[20]  C. Cordon-Cardo,et al.  Targeting cancer stem cells to suppress acquired chemotherapy resistance , 2014, Oncogene.

[21]  A. Brunetti,et al.  Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Using 3′-Deoxy-3′-[18F]-Fluorothymidine Positron Emission Tomography , 2014, Clinical Cancer Research.

[22]  Li Zhang,et al.  Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. , 2013, European journal of cancer.

[23]  Michael Peyton,et al.  An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance , 2012, Clinical Cancer Research.

[24]  Jun-ling Liu,et al.  Activation of notch‐1 enhances epithelial–mesenchymal transition in gefitinib‐acquired resistant lung cancer cells , 2012, Journal of cellular biochemistry.

[25]  Gaetano Rocco,et al.  Epithelial to Mesenchymal Transition by TGFβ-1 Induction Increases Stemness Characteristics in Primary Non Small Cell Lung Cancer Cell Line , 2011, PloS one.

[26]  A. Capobianco,et al.  Notch signalling in solid tumours: a little bit of everything but not all the time , 2011, Nature Reviews Cancer.

[27]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[28]  G. Viglietto,et al.  The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.